Idera holds out hope for IMO-2055 after negative Phase II head and neck cancer data
This article was originally published in Scrip
Executive Summary
Undeterred by topline results from a Phase II clinical trial which did not meet the primary endpoint Idera Pharmaceuticals still believes it can find ways to make its oncology drug candidate IMO-2055 work. When given in combination with ImClone's Erbitux (cetuximab) to treat recurrent or metastatic squamous cell carcinoma of the head and neck, progression-free survival did not improve.
You may also be interested in...
Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Finance Watch: Investors Remain Receptive To Biopharma, Health Care SPAC IPOs
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Finance Watch: Biopharma VC Deals Hit New Record Of $27.4bn In 2020
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
Need a specific report? 1000+ reports available
Buy Reports